Assessing cancer care value involves frameworks like the ESMO-MCBS scale, which helps measure treatment effectiveness through patient-centred and tumour-centred outcomes. Quality of life is increasingly important in clinical trials, influencing treatment choices.

The ESMO-MCBS scale also guides healthcare professionals in evaluating clinical trial benefits and impacts public policy for resource allocation.